A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Clinical trial NCT00964704 · WITHDRAWN
Trial details
- NCT number
- NCT00964704
- Sponsor
- Hoffmann-La Roche
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-01
- Primary completion
- 2013-08-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.